Biogen Inc. (BIIB)
| Previous Close | 193.18 |
| Open | 199.18 |
| Bid | 201.06 x 200 |
| Ask | 212.93 x 100 |
| Day's Range | 198.97 - 205.75 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,201,566 |
| Market Cap | 29.273B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 25.24 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Yahoo Finance Video
Biogen stock rises on Q1 results, Alzheimer's drug sales
Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi. Yahoo Finance's Anjalee Khemlani breaks down the details of the report. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
- Zacks
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
- Barrons.com
Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer’s Drug
Biogen stock moved higher after the biopharmaceutical company reported better-than-expected earnings and a hefty increase in sales of its Alzheimer’s drug. Biogen reported first-quarter adjusted earnings of $3.67 a share from revenue of $2.29 billion. Optimistic commentary from Biogen regarding its Alzheimer’s treatment Leqembi contributed to Wednesday’s gain.
